enzalutamide-sensitive human prostate cancer cell line model C4–2b cells were maintained as described previously (12 (link)). NCI-H660 cells were purchased from ATCC and maintained in suggested culture medium. C4–2b was validated by short tandem repeat DNA fingerprint with the AmpFLSTR Identifier PCR Amplification Kit (Thermo Fisher Scientific) in MD Anderson’s Characterized Cell Line Core Facility. Genomic mutation/deletion analysis for all cell lines was performed previously by targeted DNA sequencing. Palbociclib (S1116), abemaciclib (S5716), olaparib (KU-0059436), and enzalutamide (S1250) were purchased from Selleck Chemicals.
Protocol detail
Enzalutamide-resistant Prostate Cancer Model
Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link:
Access Free Full Text.
Abemaciclib
Cell lines
Cells
Culture medium
Deletion mutation
Dna fingerprint
Enzalutamide
Genomic
Genomic mutation
Human
Olaparib
Palbociclib
Prostate cancer
Short tandem repeat
Top 5 similar protocols
Variable analysis
independent variables
- Palbociclib (S1116)
- Abemaciclib (S5716)
- Olaparib (KU-0059436)
- Enzalutamide (S1250)
- Proliferation/viability of C4-2b and NCI-H660 cell lines
- C4-2b cell line maintained as described previously
- NCI-H660 cell line purchased from ATCC and maintained in suggested culture medium
- C4-2b cell line validated by short tandem repeat DNA fingerprint
- Genomic mutation/deletion analysis for all cell lines performed previously by targeted DNA sequencing
- Positive control: Not specified
- Negative control: Not specified
Annotations
Based on most similar protocols
Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.
Sign up for free or login to display all annotations
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!